Immunological treatment options for locoregionally advanced head and neck squamous cell carcinoma

Christopher Schutt, Klaus Bumm, Leonardo Mirandola, Giovanni Bernardini, Nicholas D. Cunha, Lukman Tijani, Diane Nguyen, Joehassin Cordero, Marjorie R. Jenkins, Everardo Cobos, W. Martin Kast, Maurizio Chiriva-Internati

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Patients with squamous cell carcinoma of the head and neck (HNSCC) are usually treated by a multimodal approach with surgery and/or radiochemotherapy as the mainstay of localregional treatment in cases with advanced disease. Both chemotherapy and radiation therapy have the disadvantage of causing severe side effects, while the clinical outcome of patients diagnosed with HNSCC has remained essentially unchanged over the last decade. The potential of immunotherapy is still largely unexplored. Here the authors review the current status of the art and discuss the future challenges in HNSCC treatment and prevention.

Original languageEnglish (US)
Pages (from-to)22-42
Number of pages21
JournalInternational Reviews of Immunology
Volume31
Issue number1
DOIs
StatePublished - Feb 2012

Fingerprint

Chemoradiotherapy
Art
Immunotherapy
Radiotherapy
Drug Therapy
Therapeutics
Carcinoma, squamous cell of head and neck

Keywords

  • Cancer vaccines
  • CRT
  • EGFR
  • HNSCC
  • HPV

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy

Cite this

Schutt, C., Bumm, K., Mirandola, L., Bernardini, G., Cunha, N. D., Tijani, L., ... Chiriva-Internati, M. (2012). Immunological treatment options for locoregionally advanced head and neck squamous cell carcinoma. International Reviews of Immunology, 31(1), 22-42. https://doi.org/10.3109/08830185.2011.637253

Immunological treatment options for locoregionally advanced head and neck squamous cell carcinoma. / Schutt, Christopher; Bumm, Klaus; Mirandola, Leonardo; Bernardini, Giovanni; Cunha, Nicholas D.; Tijani, Lukman; Nguyen, Diane; Cordero, Joehassin; Jenkins, Marjorie R.; Cobos, Everardo; Kast, W. Martin; Chiriva-Internati, Maurizio.

In: International Reviews of Immunology, Vol. 31, No. 1, 02.2012, p. 22-42.

Research output: Contribution to journalArticle

Schutt, C, Bumm, K, Mirandola, L, Bernardini, G, Cunha, ND, Tijani, L, Nguyen, D, Cordero, J, Jenkins, MR, Cobos, E, Kast, WM & Chiriva-Internati, M 2012, 'Immunological treatment options for locoregionally advanced head and neck squamous cell carcinoma', International Reviews of Immunology, vol. 31, no. 1, pp. 22-42. https://doi.org/10.3109/08830185.2011.637253
Schutt, Christopher ; Bumm, Klaus ; Mirandola, Leonardo ; Bernardini, Giovanni ; Cunha, Nicholas D. ; Tijani, Lukman ; Nguyen, Diane ; Cordero, Joehassin ; Jenkins, Marjorie R. ; Cobos, Everardo ; Kast, W. Martin ; Chiriva-Internati, Maurizio. / Immunological treatment options for locoregionally advanced head and neck squamous cell carcinoma. In: International Reviews of Immunology. 2012 ; Vol. 31, No. 1. pp. 22-42.
@article{f022fadaede64da7b196ef38c2943578,
title = "Immunological treatment options for locoregionally advanced head and neck squamous cell carcinoma",
abstract = "Patients with squamous cell carcinoma of the head and neck (HNSCC) are usually treated by a multimodal approach with surgery and/or radiochemotherapy as the mainstay of localregional treatment in cases with advanced disease. Both chemotherapy and radiation therapy have the disadvantage of causing severe side effects, while the clinical outcome of patients diagnosed with HNSCC has remained essentially unchanged over the last decade. The potential of immunotherapy is still largely unexplored. Here the authors review the current status of the art and discuss the future challenges in HNSCC treatment and prevention.",
keywords = "Cancer vaccines, CRT, EGFR, HNSCC, HPV",
author = "Christopher Schutt and Klaus Bumm and Leonardo Mirandola and Giovanni Bernardini and Cunha, {Nicholas D.} and Lukman Tijani and Diane Nguyen and Joehassin Cordero and Jenkins, {Marjorie R.} and Everardo Cobos and Kast, {W. Martin} and Maurizio Chiriva-Internati",
year = "2012",
month = "2",
doi = "10.3109/08830185.2011.637253",
language = "English (US)",
volume = "31",
pages = "22--42",
journal = "International Reviews of Immunology",
issn = "0883-0185",
publisher = "Informa Healthcare",
number = "1",

}

TY - JOUR

T1 - Immunological treatment options for locoregionally advanced head and neck squamous cell carcinoma

AU - Schutt, Christopher

AU - Bumm, Klaus

AU - Mirandola, Leonardo

AU - Bernardini, Giovanni

AU - Cunha, Nicholas D.

AU - Tijani, Lukman

AU - Nguyen, Diane

AU - Cordero, Joehassin

AU - Jenkins, Marjorie R.

AU - Cobos, Everardo

AU - Kast, W. Martin

AU - Chiriva-Internati, Maurizio

PY - 2012/2

Y1 - 2012/2

N2 - Patients with squamous cell carcinoma of the head and neck (HNSCC) are usually treated by a multimodal approach with surgery and/or radiochemotherapy as the mainstay of localregional treatment in cases with advanced disease. Both chemotherapy and radiation therapy have the disadvantage of causing severe side effects, while the clinical outcome of patients diagnosed with HNSCC has remained essentially unchanged over the last decade. The potential of immunotherapy is still largely unexplored. Here the authors review the current status of the art and discuss the future challenges in HNSCC treatment and prevention.

AB - Patients with squamous cell carcinoma of the head and neck (HNSCC) are usually treated by a multimodal approach with surgery and/or radiochemotherapy as the mainstay of localregional treatment in cases with advanced disease. Both chemotherapy and radiation therapy have the disadvantage of causing severe side effects, while the clinical outcome of patients diagnosed with HNSCC has remained essentially unchanged over the last decade. The potential of immunotherapy is still largely unexplored. Here the authors review the current status of the art and discuss the future challenges in HNSCC treatment and prevention.

KW - Cancer vaccines

KW - CRT

KW - EGFR

KW - HNSCC

KW - HPV

UR - http://www.scopus.com/inward/record.url?scp=84856082393&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84856082393&partnerID=8YFLogxK

U2 - 10.3109/08830185.2011.637253

DO - 10.3109/08830185.2011.637253

M3 - Article

VL - 31

SP - 22

EP - 42

JO - International Reviews of Immunology

JF - International Reviews of Immunology

SN - 0883-0185

IS - 1

ER -